by Lisa Blum | Oct 6, 2021
Myeloid immune cells are important mediators in the pathology of many diseases, especially in diseases associated with chronic inflammation (DACI). Recent advancements in molecular profiling technologies have led to the generation of large data sets, many of those not...
by Lisa Blum | Feb 3, 2021
Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this therapy are being developed for distinct...
by Lisa Blum | Jan 12, 2021
Increasing European ICU Performance Capacity. The vision and key objective of ICU4Covid is to deliver intensive care medicine fit for the fight against COVID-19 to the EU citizen and the health workforce rapidly and at scale by clinically validating and deploying the...
by Lisa Blum | Feb 24, 2020
The project ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to...
by Lisa Blum | Dec 2, 2019
The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy safety and efficacy. Existing nonclinical models do not adequately represent the complexity of the immune system and its...
